Christopher Evans
Adult Health · Raleigh, NCNPI 1528400272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Viiv Healthcare Company at 41.1% of the total. Reporting peaked in 2021 at $1,831 and has fallen 78.4% since, to $396 in 2024. Among adult health clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$2K
- Johnson & Johnson$483
- Merck$246
- Janssen Products, LP$216
- Napo Pharmaceuticals Inc$141
- plus $179 from 2 others
What the payments were for
- Speaking & faculty fees$711%
- Food & beverage$4,49493%
- Education$2555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 116 | $1,983 |
| Gilead | 88 | $1,573 |
| Johnson & Johnson(2 entities) | 28 | $483 |
| Merck | 17 | $246 |
| Janssen Products, LP | 3 | $216 |
| Napo Pharmaceuticals Inc | 8 | $141 |
| AbbVie | 6 | $134 |
| Janssen Scientific Affairs, LLC | 3 | $45 |
How this compares
$4,820 in reported general payments places this provider in the 90th percentile of 614 adult health providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 207 | $856,748 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 23 | $107,137 |
| CabenuvaCabotegravir/Rilpivirine | 17 | $99,791 |
| DovatoDolutegravir Sodium/Lamivudine | 33 | $98,434 |
| TivicayDolutegravir Sodium | 33 | $74,966 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $51,416 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $40,319 |
| IsentressRaltegravir Potassium | 11 | $21,525 |
| ValacyclovirValacyclovir Hcl | 38 | $1,940 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $692 |
| Lamivudine | 11 | $466 |
| Gabapentin | 25 | $263 |
| Rosuvastatin Calcium | 23 | $199 |
| Atorvastatin Calcium | 41 | $187 |
| Potassium Chloride | 14 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,573 | $897,066224 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Tivicay, Triumeq | $1,983 | $324,60897 claims |
| Janssen Products, LPSymtuza | $216 | $107,13723 claims |
| MerckIsentress | $246 | $21,52511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 adult health providers in North Carolina.
Other adult health in Raleigh
- Robert DodgeRaleigh$311K
- Henry VanpalaRaleigh$110K
- Priya KosRaleigh$10K
- Patricia McGrailRaleigh$10K
- Alyssa KianiRaleigh$8K
- Katherine StahlRaleigh$5K
- Kimberly CampDurham$147K
- Jolene SpencerWashington$83K
- Felicia RichardsonGreenville$64K
- Anna BooneReidsville$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.